1. Home
  2. XBIO vs HSCS Comparison

XBIO vs HSCS Comparison

Compare XBIO & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.07

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Logo Heart Test Laboratories Inc.

HSCS

Heart Test Laboratories Inc.

HOLD

Current Price

$1.82

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIO
HSCS
Founded
N/A
2007
Country
United States
United States
Employees
2
12
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
6.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XBIO
HSCS
Price
$3.07
$1.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
14.4K
34.4K
Earning Date
05-13-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$1.63
52 Week High
$13.93
$6.47

Technical Indicators

Market Signals
Indicator
XBIO
HSCS
Relative Strength Index (RSI) 38.44 45.25
Support Level $2.74 $1.77
Resistance Level $3.44 $2.18
Average True Range (ATR) 0.17 0.16
MACD -0.03 -0.00
Stochastic Oscillator 0.00 25.93

Price Performance

Historical Comparison
XBIO
HSCS

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

Share on Social Networks: